TABLE 1.
Therapeutic Interventions in EAE That are Relevant to the JAK/STAT Pathway.
| Drug | Property | Disease(s) | Mechanisms of action relevant to JAK/STAT | Reference(s) |
|---|---|---|---|---|
| Plumbagin | Natural compound | EAE | Target JAK1/2 and STAT1/3/4 | 142 |
| Berbamine | Natural compound | EAE | Up-regulation of SLIM to promote STAT4 degradation | 143 |
| Berberine | Natural compound | EAE | Target TYK2/JAK1/2 and STAT1/3/4 | 144 |
| Curcumin | Natural compound | EAE | Target JAK2/TYK2 and STAT3/4 | 163 |
| Quercetin | Natural compound | EAE | Target JAK2/TYK2 and STAT3/4 | 161 |
| 1,25 Dihydroxyvitamin-D3 | Natural compound | EAE | Target JAK2/TYK2 and STAT3/4 | 147 |
| Tripchlorolide | Natural compound | EAE | Target JAK2 and STAT1/3 | 148 |
| Cornel iridoid glycoside | Natural compound | EAE | Target JAK1/3 and STAT1/3 | 149 |
| Glatiramer acetate | Pharmacologic compound | EAE | Target STAT1 | 150 |
| Glatiramer acetate | Pharmacologic compound | EAE | Target JAK2/TYK2 and STAT3/4 | 153 |
| Fumurates | Pharmacologic compound | MS/EAE | Target STAT1 | 152 |
| Laquinimod | Pharmacologic compound | EAE | Target STAT1 | 151 |
| Statins | HMG-CoA reductase inhibitors | EAE/MS | Induce SOCS1 and SOCS3, Target JAK2/TYK2 and STAT4 | 156, 157, 159 |
| COX-2 inhibitors | Pharmacologic compound | EAE | Target JAK2/TYK2 and STAT3/4 | 161 |
| GSK3 inhibitors | Pharmacologic compound | EAE | Target STAT1 | 162 |
| PPARγ agonists | Pharmacologic compound | EAE | Target JAK2/TYK2 and STAT3/4 | 163 |
| Tyrphostin B42 | JAK2 inhibitor | EAE | Target JAK2 and STAT3 | 167 |
| CEP-701 | JAK2 inhibitor | EAE | Target JAK2 | 168, 169 |
| AZD1480 | JAK1/2 inhibitor | EAE | Target JAK1/2 and STAT1/3/4 | 170 |
| ORLL-NIH001 | STAT3 inhibitor | EAU | Target STAT3 | 174 |
| Tkip | SOCS1 mimetics | EAE | Target JAK2 | 113, 175, 176 |
| SOCS1-KIR | SOCS1/3 mimetics | EAE | Target JAK2/TYK2 and STAT3 | 177, 178 |